Phase
Condition
Cystoid Macular Edema
Treatment
Jueling Mingmu decoction
intravitreal injections of 0.5mg ranibizumab
Clinical Study ID
Ages > 18 All Genders Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
Foveal center-involved macular edema (ME) lasting less than 9 months
Central Macular Thickness (CMT) greater than or equal to 250 μm
Best-Corrected Visual Acuity (BCVA) of 24-73 letters (20/40 to 20/320) in the studyeye
Initial diagnosis with no prior treatments, such as laser therapy or intravitrealinjections
Exclusion
Exclusion Criteria:
Presence of any additional macular pathology, such as age-related maculardegeneration (AMD) or diabetic retinopathy (DR) affecting the macula
Concurrent serious conditions, such as cardiovascular diseases, liver, or kidneydiseases
Concerns or doubts regarding treatment
Known allergies to the ingredients of the medication.
Study Design
Study Description
Connect with a study center
Dongyang People's Hospital
Dongyang, Zhejiang 322100
ChinaActive - Recruiting
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.